CA
ALXN

CXI Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

CXI Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Buy
+11
New +$1.18K ﹤0.01% 238

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CXI Advisors's ALXN Position: Q4 2019 in Review

CXI Advisors opened a new position in Alexion Pharmaceuticals (ALXN) in Q4 2019: 11 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #238 among its holdings.

668 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • CXI Advisors held 11 shares of Alexion Pharmaceuticals worth $1K as of Q4 2019.
  • Alexion Pharmaceuticals was a new CXI Advisors position in Q4 2019.
  • Alexion Pharmaceuticals made up ﹤0.01% of CXI Advisors's portfolio in Q4 2019, its #238 holding.
  • 668 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on CXI Advisors's 13F filing for Q4 2019, filed 27 Jan 2020.